Antileukemic effect of venetoclax and hypomethylating agents via caspase-3/GSDME-mediated pyroptosis

Abstract

GSDME-mediated pyroptosis may be a novel aspect of the antileukemic effect of Bcl-2 inhibitors. This finding offers new insights into potential biomarkers and therapeutic strategies, identifying an important mechanism explaining the clinical activity of venetoclax and HMAs in AML.